INTREPAD
A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received June 1, 2018
- Accepted in final form January 7, 2019
- First Published April 5, 2019.
Article Versions
- Previous version (April 5, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Pierre-François Meyer, MSc*,
- Jennifer Tremblay-Mercier, MSc*,
- Jeannie Leoutsakos, PhD,
- Cécile Madjar, MSc,
- Marie-Élyse Lafaille-Maignan, PhD,
- Melissa Savard, MSc,
- Pedro Rosa-Neto, MD, PhD,
- Judes Poirier, PhD†,
- Pierre Etienne, MD†,
- John Breitner, MD, MPH†;
- for the PREVENT-AD Research Group
- Pierre-François Meyer, MSc*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Lazlo & Etelka Kollar fellowship, McGill University (2) Canada First Research Excellence Fund, awarded to McGill University for the Healthy Brains for Healthy Lives initiative
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jennifer Tremblay-Mercier, MSc*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeannie Leoutsakos, PhD,
NONE
NONE
NONE
Journal of Alzheimer Disease, Associate Editor, 2016-present (not compensated) PLOS One, Associate Editor, 2018-present (not compensated)
NONE
NONE
NONE
NONE
NONE
I serve on the NIDA Addictions IRB
NONE
NONE
NAID, R01AI117065-01A1, Co-I, 2015-2019 NIA, R01AG046274, Co-I, 2014-2019 NIA, R01AG050515, Co-I, 2016-2021 NIDA, R01DA037314, Co-I, 2015-2020 NIH, Cornell Subcontract 16060870, Co-I, 2016-2021 NIA, R01AG057725, Co-I, 2017-2021 NIMH, R01MH115487, Co-I, 2018-2021 NIAAA, R01AA024101, Co-I, 2018-2023 NIDA, R01DA041367, Co-I, 2017-2022 NHLBI, R24HL111895, Co-I, 2016-2019 NIA, R21AG056721, Co-I, 2018-2020 NIA, K23AG044441, Co-I, 2014-2019 NIA, P30AG059298, Core Co-Leader, 2018-2023 CDC, R01CE003069, Co-I, 2018-2021
NONE
Alzheimer's Association, 0266-2799-4609 , Co-I, 2015-2018 Stock/Stock Options, Medical Equipment & Materials: Merck, Rite Aid, Express Scripts Holding
NONE
NONE
NONE
NONE
NONE
NONE
- Cécile Madjar, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marie-Élyse Lafaille-Maignan, PhD,
(1) Clinical excellence committee on social services with a focus on youth, mental health and dependence for the Institut National d?excellence en sant? et en services sociaux (INESS). (2) International Market Access Consulting
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
McGill University
Kollar Scholarship
NONE
NONE
NONE
(1) Aphria, 2017-2018 (2) Illumina Inc, 2017-2018 (3) Google, 2017-2018 (4) GILEAD SCIENCES INC 2017-2018 (5) ALLERGAN PLC 2017-2018 (6) Baxter international inc 2017 (7) Celgene 2017 (8) NEUROTROPE 2017
NONE
NONE
- Melissa Savard, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pedro Rosa-Neto, MD, PhD,
(1) Enigma radiopharmaceutical (2) Kalgene
NONE
NONE
associate editor: Frontier in Aging Neurosciences
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Enigma pharmaceuticals (2) Eli-Lilly
(1) FRSQ, 35271, principal applicant, 2014-2018 (2) CIHR, 363444, co-applicant, 2016-2019 (3) CIHR, 366009, co-applicant, 2016-2020 (4) CIHR, 201312CNA-322265-CNA-CFAF-32054, co- investigator, 2014-2019
(1) Merck, Sharpe & Dohme Corporation/McGill Faculty of Medicine Grant for Translational Research
(1) Weston Brain Institute (2) Alzheimer's Association (3) Brain Canada CQDM
NONE
NONE
NONE
NONE
NONE
NONE
- Judes Poirier, PhD†,
1) Fondation Alzheimer (France)
NONE
NONE
Journal of Alzheimer's Disease, Associate Editor, 2017- 2018
NONE
Young and Centanarian, Tr?carr? (Canada), 2017 Alzheimer's Disease: The Complete Guide, 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
J.L. Levesque Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Etienne, MD†,
Ex-member of the Scientific Advisory Board of Sciformix, a consulting safety and risk management company based in Pune and Mumbai, India. Sciformix was acquired by Covance in 2018.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John Breitner, MD, MPH†;
(1) Mayo Clinic Studies on Aging, Scientific Advisory Board (NIH-funded program) (2) Data and Safety Monitoring Board, SPRINT-MIND clinical trial (NIA / NHLBI sponsor) (3) Consultant to Cerespir Pharmaceuticals
NONE
Receive occasional honoraria for industry-sponsored talks
Alzheimer's Disease and Associated Disorders, Editorial Board, 2003 - present; PLOS-One, Academics, 2009 - present; Alzheimer's and Dementia, Editorial Board, 2007 - present;
NONE
Fast Facts - Dementia. Second Edition. Health Press, 2009 (no royalties received in over two years)
NONE
Cerespir, Inc (consultant)
NONE
NONE
NONE
Research Support (gift) from Pfizer Canada
(1) Fonds de Recherche du Quebec - Sante PI 2012-2015
(1) Program support from McGill University Faculty of Medicine
(2) Research support from the Douglas Hospital Research Centre and the Douglas Hospital Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- for the PREVENT-AD Research Group
- From the McGill Centre for Integrative Neuroscience, Montreal Neurological Institute (C.M.), and McGill University Research Centre for Studies in Aging (M.S., P.R.-N.), McGill University (P.-F.M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.); StoP-AD Centre (P.-F.M., J.T.-M., M.-E.L.-M., P.R.-N., J.P., P.E., J.B.), Douglas Mental Health University Institute Research Centre, Montréal, Canada; and John Hopkins University (J.L.), Baltimore, MD.
- Correspondence
Dr. Breitner john.breitner{at}mcgill.ca
Article usage
Cited By...
Letters: Rapid online correspondence
- Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
- John Breitner, geriatric psychiatrist, Douglas Hospital Research Centre
- Pierre-Francois Meyer, PhD student, Integrated Program in Neuroscience, McGill University
Submitted June 11, 2019 - Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
- J. Wesson Ashford, Physician, Psychiatrist, and War Related Illness and Injury Study Center Director, Stanford University, VA Palo Alto Health Care System
Submitted April 17, 2019
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan